Children (iACT for Children) (3) . The European Commission has funded a significant amount of pediatric research. For example, 19 projects were funded under European Union (EU) 7th Framework Programme for Research and Technological Development (FP7) to support research into off-patent medicines (4) . However, Horizon 2020 (H2020), The EU Framework Programme for Research and Innovation and other major funders require combined lobbying from a pediatric research alliance including all pediatric/child health societies and stakeholders to ensure children research is adequately funded. For example, the Royal College of Paediatric and Child Health, UK (RCPCH) has led the establishment of a UK Child Health Research Collaboration, providing a forum for children's research charities to come together to fund, advocate, or lobby. This and similar work by the pediatric oncology community needs to be generalized across all European countries, therapeutic areas and pediatric age groups. There are commonalities across the pediatric age groups that facilitate the development of a vibrant research community. The RICHE project is a response to a call to clearly identify gaps in European child health research, and to provide justified guidance on priorities for investments in research over the next decade (5) .
Participatory re search including parent and family groups in all areas of the research from inception to result publication is evolving and will increase the visibility and lobbying potential for Pediatric Research as exemplified in the RCPCH Children's Research Charter. The European Network of Young People's Advisory Groups has developed ways to present the voices of children and young people to other stakeholders at all stages of research. A number of countries have developed, or are developing, framework and infrastructural support for children's research. Recent advances on collaborative pediatric medicine for children such as the Global Research in Pediatrics-Network of Excellence (GRiP), have stimulated and facilitated the development and safe use of medicines in children (http://www.grip-network.org/index. php/cms/en/Home). The development of common standards
The future of pediatric research Policy Commentary and regulatory approaches is an urgent requirement. The International Neonatal Consortium is an exemplar of this (6, 7) . In addition, Global funding Bill and Melinda Gates has dramatically increased funding to children especially to neonates and this success may be a template for more private sponsoring of pediatric research.
Education and training about research is essential for the future development of child health. A number of initiatives have been developed. For example, the GRiP has developed an International Masters Degree in Pediatric Drug Development and Evaluation together with a 1-to 2-d roadshow about the study of medicines in children. The RCPCH is introducing training in generic research competencies into training for all pediatricians (8) .
The future of pediatric research depends on concerted action to develop research infrastructure and true engagement with children, young people, and families. This needs support from policymakers (who need to be lobbied), educators, and the broad child health community. Then, the creativity and energy of child health professionals will be harnessed effectively to the needs of babies, children, and young people.
Action points:
• Develop a pan-European forum for discussion among learned societies and other groups about priorities and key messages • Lobby European Commission and national governments about the priorities and key messages • Respond to the consultation on the 10-y review of the Pediatric Regulation to ensure that children's needs continue to be met
• Focus on medicines research as an easy to justify activity but generalize lessons learnt to other aspects of child health
